LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

Details

Request a copyRequest a copy
Serval ID
serval:BIB_AA7296087B5B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Journal
Annals of Oncology
Author(s)
Banerjee S., Ottevanger P.B., Sarivalasis A., Le Scodan R., Montes A., Kroep J.R., Romeo Marin M., Casado Herraez A., Auvray-Kuentz M., Westermann A.M., Lucas B., Dangaj D., Herrera F., Wolfer A., Coens C., Vanlancker M.B., Kandalaft L., Coukos G.
ISSN
0923-7534
Publication state
Published
Issued date
09/2021
Volume
32
Pages
S1308
Language
english
Keywords
Oncology, Hematology
OAI-PMH
oai:serval.unil.ch:BIB_AA7296087B5B
DOI
10.1016/j.annonc.2021.08.2109
Web of science
000700527703508
Open Access
Yes
Create date
12/01/2022 11:26
Last modification date
13/01/2022 7:33
Usage data